ramatroban has been researched along with 6-ketoprostaglandin f1 alpha in 1 studies
| Studies (ramatroban) | Trials (ramatroban) | Recent Studies (post-2010) (ramatroban) | Studies (6-ketoprostaglandin f1 alpha) | Trials (6-ketoprostaglandin f1 alpha) | Recent Studies (post-2010) (6-ketoprostaglandin f1 alpha) |
|---|---|---|---|---|---|
| 142 | 10 | 28 | 4,832 | 294 | 150 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altavilla, D; Campo, GM; Canale, P; Caputi, AP; Ioculano, M; Sardella, A; Squadrito, F; Squadrito, G; Urna, G | 1 |
1 other study(ies) available for ramatroban and 6-ketoprostaglandin f1 alpha
| Article | Year |
|---|---|
Beneficial effects of BAY u3405, a novel thromboxane A2 receptor antagonist, in splanchnic artery occlusion shock.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arterial Occlusive Diseases; Blood Pressure; Carbazoles; Macrophages; Male; Myocardial Depressant Factor; Peroxidase; Phagocytosis; Rats; Rats, Sprague-Dawley; Receptors, Thromboxane; Shock; Splanchnic Circulation; Sulfonamides; Survival Rate; Thromboxane A2; Thromboxane B2 | 1994 |